Quake-related Demand Drives Mitsubishi Tanabe Sales
This article was originally published in PharmAsia News
Mitsubishi Tanabe Pharma first quarter results show strong demand following the earthquake in northern Japan drove a sales increase of 1.2%
You may also be interested in...
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.
US regulators refused to accept the file for one of Y-mAbs's neuroblasoma drugs – omburtamab – in October but have given the green light to a second one, naxitamab.